FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely, to oncology, and can be used in treatment of locally advanced and disseminated renal cell carcinoma. Method includes determination of absolute concentration of cells with phenotypes CD57+ in mm (X5) and CD4+CD25+Treg in mm3 (X4), as well as levels of spontaneous production of interleukine-6 in pg/ml (X3), interleukine-8 in pg/ml (X2) and interferon-γ in pg/ml (XI). Obtained data are used to calculate discriminant functions and the largest value of the function is used to predict patient's life duration and to administer treatment depending on predicted life duration.
EFFECT: application of invention allows to carry out adequate treatment of patients with different life duration, to optimise regimens of medication introduction, to improve remote results of treatment of patients with disseminated and locally advanced renal cell carcinoma.
12 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING DISSEMINATED RENAL CARCINOMA | 2009 |
|
RU2409382C1 |
| METHOD FOR LIFESPAN EVALUATION IN PATIENTS WITH LOCALLY ADVANCED AND DISSEMINATED RENAL CELL CARCINOMA | 2009 |
|
RU2405150C1 |
| METHOD OF TREATING RENAL CELL CARCINOMA | 2019 |
|
RU2712454C1 |
| METHOD FOR TREATING THE CASES OF RENAL CELL CARCINOMA | 2001 |
|
RU2179859C1 |
| METHOD OF TREATING DISSEMINATED RENAL CELL CARCINOMA | 2019 |
|
RU2715567C1 |
| METHOD OF TREATMENT OF DISSEMINATED RENAL CELL CANCER | 2017 |
|
RU2681300C1 |
| METHOD FOR TREATING THE CASES OF URINARY BLADDER CANCER | 2005 |
|
RU2276605C1 |
| METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
| METHOD FOR EVALUATING THE IMMEDIATE RESULTS OF TREATMENT OF DISSEMINATED RENAL CELL CARCINOMA | 2020 |
|
RU2751086C1 |
| METHOD OF TREATING PATIENTS WITH METASTASES IN LYMPH NODES AND OLIGOMETASTATIC DISEASE IN BONES OF SKELETON IN PROSTATE CANCER | 2018 |
|
RU2695348C2 |
